NervGen Pharma Corp.: NervGen Pharma Closes US$15MM Private Placement and Appoints Dr. Adam Rogers to Board of Directors

Vancouver, British Columbia--(Newsfile Corp. - July 14, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to developing a first-in-class

Related Keywords

Boston ,Massachusetts ,United States ,Waltham ,Canada ,United Kingdom ,Vancouver ,British Columbia ,British ,Canadian ,Hemera Biosciences ,Adam Rogers ,Bill Adams ,Suzanne Adams ,Huitt Tracey ,England Eye Center ,Emory University Board Of Trustees ,Linkedin ,Companya Common Share ,Nervgen Pharma Corp ,Family Inc ,Tufts Medical Center Boston ,Emory School Of Medicine ,Facebook ,Regulation Services Provider ,Venture Exchange ,Pursuant To National Instrument ,British Columbia Newsfile Corp ,Securities Of The Company ,Emory University College ,Company Annual Information Form ,Nervgen The Company ,Corporate Communications ,Janssen Pharmaceuticals ,Johnson ,Biosciences Holdings ,Gen Pharma ,Private Placement ,Bill Radvak ,Jerry Silver ,Chief Executive Officer ,Emory School ,Assistant Professor ,New England Eye Center ,Tufts Medical Center ,One Family Inc ,Emory University Board ,Common Shares ,Each Warrant ,Common Share ,National Instrument ,Early Warning System ,Related Take Over Bid ,Insider Reporting Issues ,United States Securities Act ,Chief Financial ,Annual Information Form ,Management Discussion ,Nervgen ,Dharma ,Orp ,Loses ,35mm ,Private ,Placement ,Ppoints ,Dam ,Rogers ,Board ,Directors ,